Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05941806 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Prophylactic Use of Tamsulosin in the Prevention of Post-operative Urinary Retention in Men After Rectum Resection

Study acronym: R-POUR
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Primary completion date: Jul 30, 2025 to Jul 30, 2027
    • Start date changed from estimate of Aug 1, 2023 to Nov 10, 2023
    • Study sites: 2 to 1
    • Study completion date: Jul 30, 2025 to Jul 30, 2028
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study will be a phase III double-blind randomized clinical trial. Participants will be recruited from the Department of General Surgery of the CHU de Québec - Saint-François-d'Assise and Hôtel-Dieu de Québec. The primary outcomes are the incidence of postoperative urinary retention in men undergoing rectal resection and the efficacy of prophylactic tamsulosin to prevent this type of complication.The secondary outcomes are the length of stay between experimental and placebo groups, the number of urinary catheterizations, the number of urine catheter reinsertions and total duration of urinary catheter being in-situ.
Trial Details
NCT Number NCT05941806
Lead Sponsor CHU de Quebec-Universite Laval
Collaborators: Fédération des médecins résidents du Québec
Conditions
(from sponsor)		 Urinary Retention, Colorectal Surgery, Rectal Resection, Post-operative Urinary Retention, Tamsulosin
Related terms Urinary Retention
Enrollment 220 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov